全身性エリテマトーデス、特発性炎症性筋疾患、または関節リウマチの成人患者を対象に、AZD5492 の安全性、忍容性、薬物動態、および薬力学を調査する研究。

基本情報

NCT ID

NCT06916806

ステータス

募集中

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

72

治験依頼者名

AstraZeneca

概要

The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: • The study duration will be a minimum of 180 days in addition to the screening period. Additional follow-up visits may be required up to 12 months from study start. * Depending on the study part they are assigned to, participants will be administered AZD5492 once (Part 1) or twice (Part 2). * Study visits will occur at: Screening, Days 1-4, 8, 15, 22, 30, 60, 90, 120, 150, and 180 in Part 1, Screening, Days 1-4, 8-11, 15, 22, 29, 43, 60, 90, 120, 150, and 180 in Part 2.

対象疾患

介入

依頼者（Sponsor）